[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 34 of about 34
1. Tefilli MV, Stefani SD, Mariano MB: Urethral metastasis of lung carcinoma with germinative cell features. Int Braz J Urol; 2003 Sep-Oct;29(5):431-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urethral metastasis of lung carcinoma with germinative cell features.
  • INTRODUCTION: We present the case of a patient with urethral metastasis of a lung carcinoma with germinative cell features.
  • Patient was being treated with chemotherapy and radiotherapy during the past 3 months due to primary carcinoma of the lung with brain metastasis.
  • Biopsy specimens, obtained from the lung, brain and urethra tumors, revealed the same neoplasia, with definitive diagnosis being undifferentiated giant cell carcinoma of the lung with germinative features.
  • Considering his clinical condition and poor prognosis, a decision was made to treat the patient only clinically.
  • COMMENTS: As far as we were able to access, urethral metastasis from lung carcinoma had never been described in the indexed literature.
  • Due to the extremely limited experience with these tumors, there is not a defined treatment and the prognosis remains quite poor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15745589.001).
  • [ISSN] 1677-5538
  • [Journal-full-title] International braz j urol : official journal of the Brazilian Society of Urology
  • [ISO-abbreviation] Int Braz J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


2. Shoji F, Maruyama R, Okamoto T, Ikeda J, Nakamura T, Wataya H, Ichinose Y: Long-term survival after an aggressive surgical resection and chemotherapy for stage IV pulmonary giant cell carcinoma. World J Surg Oncol; 2005 Jun 2;3:32

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival after an aggressive surgical resection and chemotherapy for stage IV pulmonary giant cell carcinoma.
  • BACKGROUND: Pulmonary giant cell carcinoma is one of the rare histological subtypes with pleomorphic, sarcomatoid or sarcomatous elements.
  • The prognosis of patients with this tumor tends to be poor, because surgery, irradiation and chemotherapy are not usually effective.
  • CASE PRESENTATION: We herein report a patient with pulmonary giant cell carcinoma with stage IV disease in whom aggressive multi-modality therapy resulted in a long-term survival.
  • Thereafter, two different regimens of chemotherapy and a partial resection for other site of small intestinal metastases and a splenectomy for splenic metastases were performed.
  • CONCLUSION: This is a first report of a rare case with stage IV pulmonary giant cell carcinoma who has survived long-term after undergoing aggressive surgical treatment and chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lung Cancer. 2001 Oct;34(1):91-7 [11557118.001]
  • [Cites] Eur Respir J. 2001 Dec;18(6):1059-68 [11829087.001]
  • [Cites] Clin Chest Med. 2002 Mar;23(1):65-81, viii [11901921.001]
  • [Cites] Cancer. 1994 Jun 15;73(12):2936-45 [8199991.001]
  • [Cites] J Clin Oncol. 2004 Jan 15;22(2):330-53 [14691125.001]
  • [Cites] Cancer. 1995 Jan 1;75(1 Suppl):191-202 [8000996.001]
  • [Cites] J Thorac Cardiovasc Surg. 2002 Apr;123(4):695-9 [11986597.001]
  • (PMID = 15929799.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1173139
  •  go-up   go-down


3. Hillman GG, Singh-Gupta V, Al-Bashir AK, Zhang H, Yunker CK, Patel AD, Sethi S, Abrams J, Haacke EM: Dynamic contrast-enhanced magnetic resonance imaging of sunitinib-induced vascular changes to schedule chemotherapy in renal cell carcinoma xenograft tumors. Transl Oncol; 2010;3(5):293-306
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dynamic contrast-enhanced magnetic resonance imaging of sunitinib-induced vascular changes to schedule chemotherapy in renal cell carcinoma xenograft tumors.
  • In an attempt to develop better therapeutic approaches for metastatic renal cell carcinoma (RCC), the combination of the antiangiogenic drug sunitinib with gemcitabine was studied.
  • We established an effective and nontoxic schedule of sunitinib combined with gemcitabine consisting of pretreatment with sunitinib for 3 days followed by four treatments of gemcitabine at 20 mg/kg given 3 days apart while continuing daily sunitinib treatment.
  • This treatment caused significant tumor growth inhibition resulting in small residual tumor nodules exhibiting giant tumor cells with degenerative changes, which were observed both in kidney tumors and in spontaneous lung metastases, suggesting a systemic antitumor response.
  • The combined therapy caused a significant increase in mouse survival.
  • These studies show that DCE-MRI can be used to select the dose and schedule of antiangiogenic drugs to schedule chemotherapy and improve its efficacy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20885892.001).
  • [ISSN] 1936-5233
  • [Journal-full-title] Translational oncology
  • [ISO-abbreviation] Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2935633
  •  go-up   go-down


Advertisement
4. Tomasković I, Sorić T, Trnski D, Ruzić B, Kraus O: Giant testicular mixed germ cell tumor. a case report. Med Princ Pract; 2004 Mar-Apr;13(2):111-3
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant testicular mixed germ cell tumor. a case report.
  • OBJECTIVE: We report a case that we believe to be the largest example of a testicular mixed germ cell tumor with a clearly defined histology pattern.
  • CLINICAL PRESENTATION AND INTERVENTIONS: A 21-year-old patient consulted a urologist concerning a giant testicular mass.
  • At the time of presentation the tumor measured 29 x 20 x 16 cm, with a weight of 4,850 g.
  • Histopathology revealed a mixed germ cell tumor containing 80% of yolk sack tumor, 10% of teratoma and 10% of embryonal carcinoma.
  • Orchiectomy and chemotherapy were successful in the treatment of primary tumor and bilateral lung metastases.
  • [MeSH-major] Germinoma / diagnosis. Testicular Neoplasms / diagnosis
  • [MeSH-minor] Adult. Humans. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 S. Karger AG, Basel
  • (PMID = 14755145.001).
  • [ISSN] 1011-7571
  • [Journal-full-title] Medical principles and practice : international journal of the Kuwait University, Health Science Centre
  • [ISO-abbreviation] Med Princ Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


5. Faisham WI, Zulmi W, Halim AS, Biswal BM, Mutum SS, Ezane AM: Aggressive giant cell tumour of bone. Singapore Med J; 2006 Aug;47(8):679-83
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive giant cell tumour of bone.
  • INTRODUCTION: The surgical treatment of Stage III or aggressive giant cell tumour of the bone, whether to perform intralesional or en-bloc resection, remains controversial.
  • METHODS: The data of 20 consecutive patients with Stage III giant cell tumour were retrospectively reviewed to determine the local control and oncological outcome after treatment with wide resection.
  • Ten patients required free vascularised tissue transfer to cover massive soft tissue defect.
  • Two patients with multiple lung metastases were treated with chemotherapy and the disease remained non-progressive.
  • The remaining two patients who refused chemotherapy showed radiological progression, and one succumbed to the disease with massive haemoptysis.
  • CONCLUSION: Aggressive giant cell tumour of bone should be treated with wide resection for better local control, and treatment of pulmonary metastases is mandatory for overall prognosis.
  • [MeSH-major] Bone Neoplasms / surgery. Carcinoma, Giant Cell / surgery. Treatment Outcome
  • [MeSH-minor] Adult. Disease Progression. Female. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16865207.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


6. Liu-Jarin X, Stoopler MB, Raftopoulos H, Ginsburg M, Gorenstein L, Borczuk AC: Histologic assessment of non-small cell lung carcinoma after neoadjuvant therapy. Mod Pathol; 2003 Nov;16(11):1102-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histologic assessment of non-small cell lung carcinoma after neoadjuvant therapy.
  • Chemotherapy or chemoradiation is often used in Stage IIIA non-small cell lung carcinoma before surgical resection (neoadjuvant therapy).
  • In reviewing the histopathology of such tumors after resection, the recognition that the pathologic changes are related to prior therapy and the assessment of tumor regression are both of importance.
  • To refine histologic parameters for tumor regression and describe patterns of tumor reaction to therapy, we identified 30 lobectomy or pneumonectomy specimens from 1996-2000 in which neoadjuvant therapy was received before surgical resection.
  • Histologic patterns of treatment-induced tumor regression were analyzed semiquantitatively and included necrosis, fibrosis, mixed inflammatory infiltrate, foamy macrophages, and giant cells.
  • To identify clinical and histologic parameters that correlate with treatment response, the 30 specimens were graded for tumor regression.
  • No correlation was found between tumor regression and age, gender, or type of therapy (chemoradiation versus chemotherapy alone).
  • Squamous cell carcinoma showed a significantly higher rate of response than adenocarcinoma (P =.04), with a significant number of adenocarcinomas in the nonresponder subgroup (P =.05).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Neoadjuvant Therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / radiography. Adenocarcinoma / radiotherapy. Adult. Aged. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiography. Carcinoma, Squamous Cell / radiotherapy. Combined Modality Therapy. Female. Fibrosis. Humans. Male. Middle Aged. Neoplasm Staging. Survival Analysis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14614049.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Maruyama T, Kubo M, Shinchou M, Hashimoto T, Mitsui Y, Ueda Y, Suzuki T, Higuchi Y, Qui J, Kondoh N, Nojima M, Yamamoto S, Shima H, Hirota S: [Case with renal pelvic carcinoma with giant hydronephrosis]. Hinyokika Kiyo; 2008 Nov;54(11):727-31
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case with renal pelvic carcinoma with giant hydronephrosis].
  • A 62-year-old man consulted us for further examination of left giant hydronephrosis which was accidentally found by abdominal ultrasonography.
  • Computed tomography (CT) revealed left giant hydronephrosis containing high-density fluid which was suspected of hemorrhage in the renal pelvis.
  • Systemic examination by CT and magnetic resonance imaging (MRI) showed renal pelvic tumors in the left kidney as well as multiple metastatic lesions in the lung, liver and bone.
  • Pathological examination of the left renal pelvic tumors obtained by biopsy showed high-grade urothelial carcinoma.
  • Although systemic and intra-arterial chemotherapy showed partial response in the metastatic lesions, he died of cancer 1 year and 3 months after the first diagnosis.
  • [MeSH-major] Carcinoma, Transitional Cell / diagnosis. Hydronephrosis / etiology. Kidney Neoplasms / diagnosis. Kidney Pelvis
  • [MeSH-minor] Bone Neoplasms / secondary. Diagnostic Imaging. Fatal Outcome. Humans. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19068727.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 22
  •  go-up   go-down


8. Kodama T, Miyazaki K, Satoh H, Hitomi S, Ohtsuka M: Giant cell lung carcinoma in a man with acquired immunodeficiency syndrome. Med Oncol; 2009;26(2):167-9
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cell lung carcinoma in a man with acquired immunodeficiency syndrome.
  • A 66-year-old man, who was discovered to have human immunodeficiency virus (HIV) infection 22 months previously and was treated with highly active antiretroviral (HAART) therapy, developed giant cell carcinoma of the lung.
  • In English literature, this is the first case of such cell type of lung cancer during HAART therapy.
  • Since giant cell carcinoma of the lung occurs mainly in elderly men who smoke heavily, there may not be a possibility that the HIV or HAART was causative in our patient.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Carcinoma, Giant Cell / diagnosis. Lung Neoplasms / diagnosis
  • [MeSH-minor] Aged. Antiretroviral Therapy, Highly Active. Fatal Outcome. HIV Infections / complications. HIV Infections / drug therapy. Humans. Male

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2003 Mar;27(3):311-24 [12604887.001]
  • [Cites] Radiology. 2004 Aug;232(2):554-9 [15215543.001]
  • [Cites] J Thorac Oncol. 2015 Sep;10 (9):1240-1242 [26291007.001]
  • [Cites] J Thorac Oncol. 2007 Apr;2(4):268-72 [17409796.001]
  • [Cites] Eur J Cardiothorac Surg. 2007 Dec;32(6):873-6 [17942316.001]
  • [Cites] Lung Cancer. 2007 Oct;58(1):112-5 [17574296.001]
  • [Cites] Am J Surg Pathol. 2008 Nov;32(11):1727-35 [18769330.001]
  • [Cites] Cancer. 2000 Feb 1;88(3):563-9 [10649248.001]
  • [Cites] An Med Interna. 2001 Jun;18(6):336-7 [11503583.001]
  • [Cites] Lung Cancer. 2001 Oct;34(1):91-7 [11557118.001]
  • [Cites] Med Oncol. 2004;21(2):109-15 [15299182.001]
  • [Cites] HIV Med. 2004 Mar;5(2):110-4 [15012651.001]
  • [Cites] Oncol Rep. 2007 May;17(5):1121-6 [17390054.001]
  • [Cites] Lung. 2004;182(6):331-41 [15765925.001]
  • [Cites] Lung Cancer. 2006 Jan;51(1):1-11 [16300854.001]
  • [Cites] Ann Thorac Surg. 2004 Nov;78(5):1742-7 [15511465.001]
  • [Cites] J Thorac Cardiovasc Surg. 2007 Sep;134(3):619-23 [17723808.001]
  • [Cites] Cancer. 1994 Jun 15;73(12):2936-45 [8199991.001]
  • [Cites] J Clin Oncol. 2006 Mar 20;24(9):1383-8 [16549832.001]
  • (PMID = 18937080.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Yasunaga M, Ohishi Y, Nishimura I, Tamiya S, Iwasa A, Takagi E, Inoue T, Yahata H, Kobayashi H, Wake N, Tsuneyoshi M: Ovarian undifferentiated carcinoma resembling giant cell carcinoma of the lung. Pathol Int; 2008 Apr;58(4):244-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian undifferentiated carcinoma resembling giant cell carcinoma of the lung.
  • Giant cell carcinoma (GCC) is a highly aggressive variant of sarcomatoid carcinoma of the lung.
  • To date, however, there have been no reported cases of ovarian carcinoma mainly composed of GCC.
  • Herein is reported the case of a 54-year-old Japanese woman with an undifferentiated ovarian carcinoma producing granulocyte colony-stimulating factor (G-CSF) and an inflammatory cytokine.
  • Histologically, the tumor was composed of cohesive nests or discohesive pleomorphic mononucleated or multinucleated tumor giant cells, accompanied by inflammatory cell infiltration and emperipolesis.
  • Adjuvant chemotherapy was administered but induced severe heart failure and severe neutropenia, probably due to the presence of hypercytokinemia and excess G-CSF.
  • Upon the appearance of these fatal side-effects the chemotherapy was immediately discontinued and replaced with radiotherapy.
  • The recognition of this type of ovarian tumor is important for clinical management, because adjuvant chemotherapy is the standard treatment for clinical management of epithelial ovarian cancer.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Giant Cell / diagnosis. Lung Neoplasms / diagnosis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Biomarkers, Tumor / metabolism. Chemotherapy, Adjuvant / adverse effects. Diagnosis, Differential. Disease-Free Survival. Fallopian Tubes / surgery. Female. Granulocyte Colony-Stimulating Factor / metabolism. Humans. Middle Aged. Mucin-1 / metabolism. Ovariectomy. Radiotherapy, Adjuvant. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18324918.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucin-1; 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


10. Hong JY, Choi MK, Uhm JE, Park MJ, Lee J, Park YH, Ahn JS, Park K, Han JH, Ahn MJ: The role of palliative chemotherapy for advanced pulmonary pleomorphic carcinoma. Med Oncol; 2009;26(3):287-91
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of palliative chemotherapy for advanced pulmonary pleomorphic carcinoma.
  • Pulmonary pleomorphic carcinoma is an uncommon malignant tumor of the lung, which has the dual cell components of spindle or giant cells and epithelial cells.
  • The objective of this study was to investigate the clinical course and efficacy of palliative chemotherapy in patients with advanced pulmonary pleomorphic carcinoma.
  • Twelve patients were diagnosed with advanced pulmonary pleomorphic carcinoma and received palliative chemotherapy from February 2000 to December 2007.
  • Among the 12 patients, five patients received gemcitabine/cisplatin, three patients received gemcitabine/carboplatin, two patients received paclitaxel/carboplatin, one patient received paclitaxel/cisplatin, and one patient received docetaxel/cisplatin as first-line chemotherapy.
  • After treatment with first-line palliative chemotherapy, seven patients (58%) had progressive disease, three patients (25%) had stable disease, and only two patients (17%) had a partial response.
  • The median overall survival from the day of initiation of first-line chemotherapy was only 8 months (95% CI, 6-10) with median follow-up of 26 months.
  • These results showed the dismal prognosis and the poor response to chemotherapy of advanced pulmonary pleomorphic carcinoma.
  • Further studies are needed to investigate whether the current strategy of palliative chemotherapy for the treatment of advanced pulmonary pleomorphic carcinoma can be justified or not.
  • Moreover, additional novel treatment approaches are required.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Neoplasms / drug therapy. Palliative Care / methods

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2003 Mar;27(3):311-24 [12604887.001]
  • [Cites] Radiology. 2004 Aug;232(2):554-9 [15215543.001]
  • [Cites] Semin Roentgenol. 2005 Apr;40(2):90-7 [15898407.001]
  • [Cites] Clin Chest Med. 2002 Mar;23(1):65-81, viii [11901921.001]
  • [Cites] Lung Cancer. 2007 Oct;58(1):112-5 [17574296.001]
  • [Cites] Eur Respir J. 2001 Dec;18(6):1059-68 [11829087.001]
  • [Cites] Lung Cancer. 2001 Oct;34(1):91-7 [11557118.001]
  • [Cites] Kyobu Geka. 2006 May;59(5):387-91 [16715890.001]
  • [Cites] Kyobu Geka. 2006 Jul;59(7):585-9 [16856536.001]
  • [Cites] J Thorac Cardiovasc Surg. 2007 Aug;134(2):399-404 [17662779.001]
  • [Cites] Nihon Kokyuki Gakkai Zasshi. 2004 Feb;42(2):164-9 [15007917.001]
  • [Cites] Ann Thorac Surg. 2004 Nov;78(5):1742-7 [15511465.001]
  • [Cites] Ann Thorac Surg. 2004 Jun;77(6):1926-30; discussion 1931 [15172237.001]
  • [Cites] Cancer. 1994 Jun 15;73(12):2936-45 [8199991.001]
  • (PMID = 18989796.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


11. Chen F, Tatsumi A, Numoto S: Combined choriocarcinoma and adenocarcinoma of the lung occurring in a man: case report and review of the literature. Cancer; 2001 Jan 1;91(1):123-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined choriocarcinoma and adenocarcinoma of the lung occurring in a man: case report and review of the literature.
  • BACKGROUND: Human chorionic gonadotropin (hCG)-producing large or giant cell carcinoma of the lung is not uncommon, but primary pulmonary choriocarcinoma is an extremely rare entity.
  • RESULTS: Computed tomography scan of the chest demonstrated an expanding thickness of the bullous wall within areas of emphysematous change in the lower lobe of the right lung.
  • Moreover, a new, round tumor near the thickness appeared and rapidly expanded evenly into the surrounding lung tissue.
  • Because of the pleural dissemination, the patient was treated with chemotherapy.
  • At last follow-up he was alive and well with a gradually increasing serum hCG-beta level in spite of chemotherapy.
  • Of the 12 cases reported to date in the English literature, 3 cases of choriocarcinoma with the coexistence of another type of pulmonary carcinoma were reported.
  • To the authors' knowledge the clinical relation between these two types of carcinoma are unknown because all cases to date have been detected at the time of autopsy.
  • Only in the current study case could the clinical course of the disease be followed and pathologic confirmation achieved, although the pathogenesis of the two types of carcinoma could not be determined.
  • [MeSH-major] Adenocarcinoma / pathology. Choriocarcinoma / pathology. Lung Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Chorionic Gonadotropin / analysis. Hemorrhage. Humans. Male. Middle Aged. Prognosis. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 American Cancer Society.
  • (PMID = 11148568.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Chorionic Gonadotropin
  • [Number-of-references] 24
  •  go-up   go-down


12. Wen ZS, Chen XQ, Wu HY, Wei WD, Rong TH: [Efficacy of gefitinib on advanced non-small cell lung cancer of bilateral diffuse or unilateral giant mass type]. Ai Zheng; 2007 Apr;26(4):415-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of gefitinib on advanced non-small cell lung cancer of bilateral diffuse or unilateral giant mass type].
  • BACKGROUND & OBJECTIVE: No more survival improvement could be obtained in advanced non-small cell lung cancer (NSCLC) today with chemotherapy or radiotherapy.
  • This study was to select NSCLC patients of suitable type by comparing the efficacy of gefitinib on advanced NSCLC of bilateral diffuse type and unilateral giant mass type.
  • METHODS: Fifty advanced NSCLC patients of bilateral diffuse type (20 cases) and unilateral mass type (30 cases) received treatment of gefitinib.
  • RESULTS: The median time to symptom improvement was significantly shorter in bilateral diffuse group than in unilateral mass group (4 days vs. 7 days, P<0.01).
  • The median progression-free time was significantly longer in bilateral diffuse group than in unilateral mass group (9.5 months vs. 3.6 months, P<0.01).
  • Drug-related adverse events were similar in the 2 groups.
  • CONCLUSIONS: Gefitinib is more effective to bilateral diffuse type NSCLC than to unilateral giant mass type NSCLC.
  • It can be considered as the second-line medicine for bilateral diffuse type NSCLC.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Quinazolines / therapeutic use
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adult. Aged. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Diarrhea / chemically induced. Disease-Free Survival. Exanthema / chemically induced. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Pruritus / chemically induced. Quality of Life. Remission Induction

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17430664.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] Clinical Trial; Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


13. Santini M, Vicidomini G, Di Marino MP, Baldi A: Solitary muscle metastasis from lung carcinoma. J Cardiovasc Surg (Torino); 2001 Oct;42(5):701-2
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary muscle metastasis from lung carcinoma.
  • Recurrence after resection of non-small cell lung carcinoma is generally associated with a poor outcome.
  • Limb muscle metastasis from lung cancer is extremely rare.
  • We present a case of a 71-year-old man who presented with a solitary metastasis to his right lower limb two months after right upper lobectomy for lung cancer (stage: T2N0M0).
  • Twenty-four months after surgical excision and chemotherapy he is alive without signs of neoplastic disease.
  • We believe that a more aggressive approach might be considered for selected patients with solitary extracranial and extra-adrenal metastasis from lung cancer.
  • [MeSH-major] Carcinoma, Giant Cell / secondary. Leg / pathology. Lung Neoplasms / pathology. Muscle Neoplasms / secondary
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Humans. Male. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11562606.001).
  • [ISSN] 0021-9509
  • [Journal-full-title] The Journal of cardiovascular surgery
  • [ISO-abbreviation] J Cardiovasc Surg (Torino)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


14. Hirai S, Hamanaka Y, Mitsui N, Morifuji K, Sutoh M: Primary lung cancer arising from the wall of a giant bulla. Ann Thorac Cardiovasc Surg; 2005 Apr;11(2):109-13
MedlinePlus Health Information. consumer health - Lung Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary lung cancer arising from the wall of a giant bulla.
  • We report a 58-year-old man who underwent surgical treatment of primary lung cancer arising from the wall of a giant bulla.
  • Chest roentgenography and computed tomography revealed multiple emphysematous bullae in the bilateral upper lobes, and a right upper giant bulla with a mass measuring 6 cm arising on the bulla wall.
  • Right upper lobectomy was performed, the postoperative pathological diagnosis was large cell carcinoma arising from the wall of a giant bulla.
  • Although the postoperative course was uneventful and he was discharged, he underwent partial resection of the jejunum for recurrence of carcinoma in the jejunum, and postoperative chemotherapy, and he was alive 20 months after that operation.
  • In general, patients with both pulmonary bullous disease and primary lung cancer have a very poor prognosis, because they receive treatment when the tumor is at an advanced stage.
  • On the basis of our review of the literature, we recommend that middle-age male patients with a giant bulla who smoke should have annual chest roentgenography and/or chest computed tomography to screen for lung cancer arising in or close to the bullous disease, and that a giant bulla should be resected in patients older than 50 years because of the high incidence of coexisting cancer and bulla, to improve the prognosis of this disease.
  • [MeSH-major] Blister / complications. Carcinoma, Large Cell / complications. Lung Diseases / complications. Lung Neoplasms / complications

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15900242.001).
  • [ISSN] 1341-1098
  • [Journal-full-title] Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia
  • [ISO-abbreviation] Ann Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 23
  •  go-up   go-down


15. Fujita K, Tsujikawa K, Murosaki N, Sugao H, Itoh Y, Takao T, Nakai Y, Miki T: [A giant testicular tumor detected with dyspnea due to lung metastases: a case report]. Hinyokika Kiyo; 2001 Aug;47(8):599-604
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A giant testicular tumor detected with dyspnea due to lung metastases: a case report].
  • Clinical examination revealed the left infant-head-sized testicular tumor, multiple lung metastases and retroperitoneal bulky lymph node metastasis with marked elevation of serum lactic dehydrogenase (LDH) and alpha-fetoprotein.
  • Left radical orchiectomy followed by the chemotherapy with etoposide and cisplatin (EP) for 4 cycles was performed.
  • The tumor weighed 1,700 g, and was pathologically diagnosed as mixed germ cell tumor consisting of embryonal carcinoma and yolk sac tumor.
  • After the treatment, the tumor markers were normalized with partial response (PR) of lung metastases and complete response (CR) of retroperitoneal lymph node metastasis.
  • Thereafter, biopsy of lung metastases through video-assisted thoracoscopic surgery (VATS) was performed, and pathologically no viable cells were detected.
  • Five months after the treatment, he was seized with convulsion due to brain metastasis with hemorrhage.
  • Therefore, a surgical resection of brain metastasis and 2nd line chemotherapy with etoposide, ifosfamide and cisplatin (VIP) chemotherapy for 3 cycles was performed.
  • The patient has been free of recurrence for 21 months after the 2nd line chemotherapy.
  • [MeSH-major] Carcinoma, Embryonal / diagnosis. Dyspnea / etiology. Endodermal Sinus Tumor / diagnosis. Lung Neoplasms / secondary. Testicular Neoplasms / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Etoposide / administration & dosage. Humans. Lymphatic Metastasis. Male. Neoplasms, Multiple Primary. Orchiectomy

  • Genetic Alliance. consumer health - Dyspnea.
  • MedlinePlus Health Information. consumer health - Breathing Problems.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11579605.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; VP-P protocol
  • [Number-of-references] 9
  •  go-up   go-down


16. Tokuyasu H, Izumi H, Mukai N, Takeda K, Sakaguchi Y, Isowa N, Shimizu E: Small cell lung cancer complicated by pulmonary sarcoidosis. Intern Med; 2010;49(18):1997-2001
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell lung cancer complicated by pulmonary sarcoidosis.
  • Chest radiography and computed tomography showed mediastinal and bilateral hilar lymphadenopathy.
  • Histological examination of the biopsy specimens obtained from the tumor in the left upper bronchus revealed small cell lung cancer, whereas examination of the specimens obtained from the left B(3) revealed noncaseating epithelioid cell granulomas containing giant cells, confirming the diagnosis of sarcoidosis.
  • The patient underwent chemotherapy with carboplatin and etoposide without any steroids.
  • After 4 courses of chemotherapy, bronchoscopic examination revealed that the tumor had shrunk, and the BALF CD4/CD8 ratio had decreased; further, no histological evidence of sarcoidosis was seen in specimens obtained from the left B(3).
  • Concomitant small cell lung cancer and sarcoidosis is rare.
  • Interestingly, cancer chemotherapy might improve pulmonary sarcoidosis.
  • [MeSH-major] Lung Neoplasms / complications. Lung Neoplasms / diagnosis. Sarcoidosis, Pulmonary / complications. Sarcoidosis, Pulmonary / diagnosis. Small Cell Lung Carcinoma / complications. Small Cell Lung Carcinoma / diagnosis

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Sarcoidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20847506.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


17. Kobayashi S, Okada S, Hasumi T, Sato N, Fujimura S: Long-term survival of a patient with stage IV pulmonary large cell carcinoma achieved by combined-modality therapy: report of a case. Surg Today; 2000;30(6):561-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival of a patient with stage IV pulmonary large cell carcinoma achieved by combined-modality therapy: report of a case.
  • We describe herein the case of a 59-year-old-man with stage IV pulmonary large cell carcinoma and a giant brain metastasis, in whom two sublines with different growth characteristics and drug sensitivities in vitro were established from the primary tumor.
  • Disease-free survival for more than 5 years after surgery was achieved by combined-modality therapy together with surgery to remove the primary tumor, radiation to the brain metastasis, and chemotherapy to presumed hematogenous dissemination.
  • Subline 1 proliferated in a monolayer of epithelial-like cells, while subline 2 showed a floating colony pattern of proliferation, resembling the typical growth characteristics of small cell lung cancer (SCLC) cells in vitro.
  • Subline 2 was sensitive to a number of drugs, namely, vincristine (VCR), cyclophosphamide (CPM), adriamycin (ADR), and cisplatin (CDDP), whereas subline 1 was resistant to many drugs.
  • The patient was treated with a combination of 44 Gy of whole-brain irradiation and a number of cycles of chemotherapy comprised of ADR, VCR, and CPM, followed by CDDP, VCR, and CPM, based on the results of sensitivity testing of the subline 2 cells.
  • In conclusion, this case report serves to demonstrate that meticulous combined-modality treatment taking tumor heterogeneity in human cancers into account may be necessary to achieve breakthroughs in current cancer therapy for advanced lung cancer.
  • [MeSH-major] Carcinoma, Large Cell / mortality. Carcinoma, Large Cell / therapy. Lung Neoplasms / mortality. Lung Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / secondary. Combined Modality Therapy. Disease-Free Survival. Humans. Lung / pathology. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Time Factors

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chest. 1996 Jan;109(1):271-6 [8549197.001]
  • [Cites] Semin Oncol. 1995 Jun;22(3 Suppl 7):32-41 [7610397.001]
  • [Cites] Arch Neurol. 1978 Nov;35(11):754-6 [718475.001]
  • [Cites] Cancer. 1981 Oct 15;48(8):1749-53 [6169424.001]
  • [Cites] Tohoku J Exp Med. 1992 Oct;168(2):375-86 [1306323.001]
  • [Cites] Cancer. 1986 Sep 1;58(5):1007-13 [3731033.001]
  • [Cites] Tohoku J Exp Med. 1998 Dec;186(4):313-22 [10328163.001]
  • [Cites] Am J Clin Oncol. 1994 Dec;17(6):527-37 [7977175.001]
  • [Cites] Cancer. 1996 Jan 15;77(2):278-83 [8625235.001]
  • [Cites] Int J Radiat Biol. 1990 Jun;57(6):1113-22 [1971838.001]
  • [Cites] Lung Cancer. 1994 Dec;11(5-6):393-400 [7704496.001]
  • [Cites] Cancer. 1986 Feb 15;57(4):804-7 [3002587.001]
  • [Cites] Cancer. 1996 May 1;77(9):1947-55 [8646697.001]
  • [Cites] Tohoku J Exp Med. 1989 Sep;159(1):1-14 [2554531.001]
  • [Cites] J Thorac Cardiovasc Surg. 1996 Jul;112(1):146-53 [8691861.001]
  • (PMID = 10883474.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


18. Raveglia F, Mezzetti M, Panigalli T, Furia S, Giuliani L, Conforti S, Meda S: Personal experience in surgical management of pulmonary pleomorphic carcinoma. Ann Thorac Surg; 2004 Nov;78(5):1742-7
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for pleomorphic carcinoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Personal experience in surgical management of pulmonary pleomorphic carcinoma.
  • BACKGROUND: Pleomorphic carcinoma is a rare epithelial malignant tumor.
  • Pulmonary pleomorphic carcinoma was introduced by the 1999 World Health Organization classification as a new peculiar type of lung carcinoma showing concurrent malignant epithelial and sarcomatoid spindle cell elements.
  • My colleagues and I report a series of patients surgically treated for pulmonary pleomorphic carcinoma to describe our experience with this malignant neoplasm.
  • METHODS: Twenty cases of pleomorphic pulmonary carcinoma were collected and studied clinicopathologically.
  • Histologic diagnosis was established by using light microscopic examination and immunohistochemistry.
  • RESULTS: We postoperatively diagnosed 20 cases of pleomorphic carcinoma: 14 cases were exclusively spindle and giant-cell carcinomas, 2 cases were spindle and giant-cell carcinoma combined with adenocarcinoma, 2 were combined with squamous cell carcinoma, and 2 were combined with large cell carcinoma.
  • CONCLUSIONS: The prognosis of patients with pleomorphic carcinoma was poor, despite surgery and adjuvant chemotherapy, because of early relapse of disease.
  • In case of preoperatively proven pulmonary pleomorphic carcinoma, surgery should be recommended to N0 patients.
  • [MeSH-major] Carcinoma / surgery. Lung Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Aged. Carcinoma, Giant Cell / mortality. Carcinoma, Giant Cell / pathology. Carcinoma, Giant Cell / surgery. Cell Differentiation. Disease-Free Survival. Female. Follow-Up Studies. Humans. Life Tables. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15511465.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 20
  •  go-up   go-down


19. Aketa A, Yamada G, Aketa K, Ohnishi T, Takahashi Y, Kudoh K, Tanaka S, Shiratori M, Takahashi H, Watanabe A, Satoh M, Abe S: [Two younger male patients with rapidly progressing pulmonary pleomorphic carcinoma]. Nihon Kokyuki Gakkai Zasshi; 2004 Feb;42(2):164-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two younger male patients with rapidly progressing pulmonary pleomorphic carcinoma].
  • We report 2 cases of pulmonary pleomorphic carcinoma.
  • The pathological diagnosis was pleomorphic carcinoma, p-T4 N2 M0.
  • After the operation, we performed systemic chemotherapy, including cisplatin and irinotecanm with little effect (PD).
  • Pathological diagnosis was pleomorphic carcinoma, p-T4 N0 M0.
  • After the operation, the mediastinum was subjected to radiation therapy.
  • We performed systemic chemotherapy with substances including cisplatin, gemcitabine and vinorelbine, but with little effect (PD).
  • Both cases had rapidly growing neoplasms showing little sensitivity to chemotherapy or radiotherapy.
  • Pulmonary pleomorphic carcinoma is suggested to be type of lung cancer with a poor prognosis when the tumor is not resected in the early stages.
  • [MeSH-major] Carcinoma / diagnosis. Carcinoma / therapy. Carcinoma, Giant Cell / diagnosis. Carcinoma, Giant Cell / therapy. Lung Neoplasms / diagnosis. Lung Neoplasms / therapy. Neoplasms, Multiple Primary
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / therapy. Adult. Age Factors. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / therapy. Chemotherapy, Adjuvant. Disease Progression. Fatal Outcome. Humans. Lymph Node Excision. Male. Neoplasm Invasiveness. Neoplasm Staging. Pneumonectomy. Radiotherapy, Adjuvant

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15007917.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


20. Koutsopoulos AV, Mavroudis D, Dambaki KI, Souglakos J, Tzortzaki EG, Drositis J, Delides GS, Georgoulias V, Stathopoulos EN: Simultaneous expression of c-erbB-1, c-erbB-2, c-erbB-3 and c-erbB-4 receptors in non-small-cell lung carcinomas: correlation with clinical outcome. Lung Cancer; 2007 Aug;57(2):193-200
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous expression of c-erbB-1, c-erbB-2, c-erbB-3 and c-erbB-4 receptors in non-small-cell lung carcinomas: correlation with clinical outcome.
  • The expression of c-erbB receptors was immunohistochemically examined in paraffin embedded specimens from non-small-cell lung carcinomas.
  • A total of 209 patients were enrolled [squamous-cell carcinomas (n=59), adenocarcinomas (n=130), large-cell carcinomas (n=15) and giant-cell carcinomas (n=5)].
  • C-erbB-1 was overexpressed in older patients, in squamous-cell carcinomas and in poorly-differentiated tumours, whereas c-erbB-2 overexpression with adenocarcinomas and poorly-differentiated tumours.
  • Response to chemotherapy was significantly reduced in patients with tumours overexpressing c-erbB-1 receptor as well as the c-erbB-1/2 and c-erbB-3/4 receptor pairs.
  • A better understanding of the overexpression of the heterodimerized partners of c-erbB family receptors may provide a useful predictive indicator of response to molecular targeted therapies with c-erbB inhibitors.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Proto-Oncogene Proteins / metabolism. Receptor, ErbB-2 / analysis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17442448.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


21. Yamane Y, Ishii G, Goto K, Kojima M, Nakao M, Shimada Y, Nishiwaki Y, Nagai K, Kohrogi H, Ochiai A: A novel histopathological evaluation method predicting the outcome of non-small cell lung cancer treated by neoadjuvant therapy: the prognostic importance of the area of residual tumor. J Thorac Oncol; 2010 Jan;5(1):49-55
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel histopathological evaluation method predicting the outcome of non-small cell lung cancer treated by neoadjuvant therapy: the prognostic importance of the area of residual tumor.
  • BACKGROUND: Histopathological evaluation method for predicting the outcome of non-small cell lung cancer (NSCLC) treated by neoadjuvant therapy has not been fully assessed.
  • The purpose of this study was to assess a novel histopathological evaluation method for predicting the outcome of NSCLC treated by neoadjuvant therapy.
  • METHODS: We reviewed the histopathology of the tumors of 53 NSCLC treated by neoadjuvant chemotherapy, chemoradiotherapy, or radiotherapy followed by complete resection and identified the histologic features produced by neoadjuvant therapy by comparing them with the histologic features of the tumors in 138 NSCLC cases treated by surgery without neoadjuvant therapy.
  • RESULTS: The proportions of cases with the histologic features "cholesterin clefts," "foreign body reactive giant cells," "stromal hyalinosis," and "bizarre nucleus in more than 50% of the cancer cells" were significantly higher in the neoadjuvant therapy group than in the surgery alone group.
  • CONCLUSIONS: Smaller ART and p (-) predict a better outcome of NSCLC treated by neoadjuvant therapy.
  • We concluded that ART is a novel histopathological evaluation method for predicting the outcome of NSCLC treated by neoadjuvant therapy.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Large Cell / pathology. Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Squamous Cell / pathology. Lung Neoplasms / pathology. Neoadjuvant Therapy. Neoplasm, Residual / pathology
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20035185.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


22. Massone PP, Lequaglie C, Macnani B, Conti B, Cataldo I: [Significance of video-assisted thoracoscopic surgery in the diagnosis and staging of primary pulmonary neoplasms]. Chir Ital; 2001 May-Jun;53(3):291-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Significance of video-assisted thoracoscopic surgery in the diagnosis and staging of primary pulmonary neoplasms].
  • The authors describe the usefulness of video-assisted thoracoscopic surgery (VATS) in the staging and diagnosis of primary lung cancer.
  • In the Oncological Thoracic Surgery Department of Milan's National Cancer Institute, over the period from January 1995 to January 2000, 46 patients, suspected of having mediastinal lymphadenopathies in the presence of lung cancer, were proposed for a VATS biopsy.
  • Forty-four patients underwent a thoracoscopic lymph node biopsy (95%), while in 2 subjects, in whom pleural metastases were found, the histological diagnosis was established by pleural metastatic nodule thoracoscopic biopsy (5%).
  • Histological examination revealed adenocarcinoma in 23 cases (50%), epidermoid carcinoma in 12 (26%), microcytoma in 8 (17%) and giant-cell lung carcinoma in 3 (7%).
  • The subsequent treatment was neoadjuvant chemotherapy for stage III A patients and chemotherapy in association with radiotherapy for stage III B subjects.
  • The patients with microcytoma underwent integrated radiotherapy and chemotherapy and pan-encephalic radiotherapy.
  • In conclusion, VATS proved extremely useful in the diagnosis and staging of patients affected by lung cancer with synchronous lymph node enlargement.
  • This procedure allowed the diagnosis of suspect involved mediastinal lymph nodes in all cases thus affected and the exclusion of lymph node disease in patients subsequently treated by lung resection in a single session.
  • The precise staging obtained then made it possible to direct the patients towards the most appropriate form of treatment.
  • [MeSH-major] Lung Neoplasms / pathology. Thoracic Surgery, Video-Assisted

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11452813.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


23. Fokkema E, De Vries EG, Groen HJ, Meijer C, Timens W: Expression of apoptosis-related proteins and morphological changes in a rat tumor model of human small cell lung cancer prior to and after treatment with radiotherapy, carboplatin, or combined treatment. Virchows Arch; 2003 Apr;442(4):349-55
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of apoptosis-related proteins and morphological changes in a rat tumor model of human small cell lung cancer prior to and after treatment with radiotherapy, carboplatin, or combined treatment.
  • PURPOSE: In order to understand the apoptosis pathway in tumor cells, differences in cell morphology and expression of apoptosis-related proteins induced by radiation and/or chemotherapy, were investigated in a rat double tumor model comparing cisplatin-sensitive and -resistant human small cell lung cancer tumors.
  • METHODS: The cisplatin-sensitive human small cell lung cancer cell line (GLC4) and its cisplatin-resistant subline (GLC4-CDDP) were each injected subcutaneously in a different hind limb of the rat.
  • After 15-17 days, radiation (10 Gy), carboplatin (25 mg/kg, intraperitoneal), combined treatment, or no treatment was administered.
  • In combined treatment, carboplatin was administered 24 h before radiation.
  • RESULTS: In the GLC4 tumor, carboplatin treatment increased tumor cell size, tumor cell size heterogeneity, and number of apoptotic tumor cells.
  • After radiation and combined treatment, these changes were more pronounced and multinuclear giant cells were observed.
  • Following radiation slight increases in tumor cell size, tumor cell size heterogeneity and number of apoptotic tumor cells were observed.
  • No multinuclear giant cells were seen.
  • After combined treatment, GLC4-CDDP showed cellular changes comparable to those in GLC4 cells after radiation or combined treatment, but no giant cells were observed.
  • After combined treatment, an increase in number of bcl-2 positive cells was found in GLC4-CDDP tumors.
  • No p21 was induced in GLC4-CDDP by any treatment modality.
  • No further changes in protein expression were induced by any treatment in GLC4 tumors.
  • CONCLUSION: Following therapy, morphological changes in cell size and cell size heterogeneity were more pronounced in GLC4 than in GLC4-CDDP tumors.
  • However, morphological changes in GLC4-CCDP tumors after treatment indicate that carboplatin plus radiotherapy may be effective also in cisplatin resistant tumor cells.
  • The increase in number of Bcl-2 positive cells after combined treatment and the consistently negative p21 status after any treatment in GLC4-CDDP may protect these tumor cells from apoptosis as a part of their resistance mechanism to cisplatin.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Apoptosis / physiology. Carboplatin / therapeutic use. Carcinoma, Small Cell / metabolism. Lung Neoplasms / metabolism. Neoplasm Proteins / metabolism
  • [MeSH-minor] Animals. Combined Modality Therapy. Disease Models, Animal. Drug Resistance, Neoplasm / physiology. Drug Resistance, Neoplasm / radiation effects. Humans. Immunoenzyme Techniques. Neoplasms, Experimental / drug therapy. Neoplasms, Experimental / metabolism. Neoplasms, Experimental / pathology. Radiotherapy. Rats. Rats, Inbred Strains. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2000 Mar 18;355(9208):949-55 [10768432.001]
  • [Cites] Radiat Res. 1998 Apr;149(4):343-9 [9525498.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Nov 1;33(4):781-96 [7591884.001]
  • [Cites] Cancer Chemother Pharmacol. 1991;28(3):159-65 [1855272.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4703-6 [9354425.001]
  • [Cites] Cancer Res. 1992 Dec 15;52(24):6885-9 [1458477.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2941-53 [10561374.001]
  • [Cites] J Natl Cancer Inst. 1999 Dec 15;91(24):2081-6 [10601378.001]
  • [Cites] Br J Cancer. 1995 Dec;72(6):1406-11 [8519652.001]
  • [Cites] Br J Cancer. 1990 Jul;62(1):72-7 [2390486.001]
  • [Cites] J Clin Oncol. 2000 May;18(10):2040-5 [10811668.001]
  • [Cites] N Engl J Med. 1999 Apr 15;340(15):1154-61 [10202166.001]
  • [Cites] Oncogene. 1996 Oct 17;13(8):1677-85 [8895513.001]
  • [Cites] Cancer Res. 1992 Mar 1;52(5):1252-8 [1737387.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(8):1652-61 [10764425.001]
  • [Cites] N Engl J Med. 1999 Apr 15;340(15):1144-53 [10202165.001]
  • [Cites] Cancer Res. 1988 Dec 1;48(23):6803-7 [2846161.001]
  • [Cites] Radiother Oncol. 1992 Apr;23(4):241-4 [1319082.001]
  • [Cites] Cancer Res. 1999 May 15;59(10):2411-6 [10344751.001]
  • [Cites] Int J Cancer. 1990 Jul 15;46(1):138-44 [2163989.001]
  • [Cites] N Engl J Med. 1992 Feb 20;326(8):524-30 [1310160.001]
  • [Cites] Clin Cancer Res. 1997 Aug;3(8):1371-81 [9815821.001]
  • [Cites] Cancer Metastasis Rev. 1992 Sep;11(2):121-39 [1327566.001]
  • [Cites] Cancer. 2000 Feb 15;88(4):876-83 [10679658.001]
  • (PMID = 12715170.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Neoplasm Proteins; BG3F62OND5 / Carboplatin
  •  go-up   go-down


24. Chen SZ, Jiang M, Zhen YS: [Correlation of HERG K+ channel protein expression to chemosensitivity of tumor cells to doxorubicin and its modulation by erythromycin]. Ai Zheng; 2005 Aug;24(8):924-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & OBJECTIVE: Previous studies have found that HERG, a kind of K(+) channel protein, is expressed in some cancers, but its expression is weak or lost in normal tissues.
  • This study was to investigate HERG expression in various cancer cell lines, its correlation with chemosensitivity of cancer cells to doxorubicin, and its biochemical modulation.
  • METHODS: HERG expression in human colon carcinoma cell line HT-29, human breast carcinoma cell line MCF-7, human lung carcinoma cell line A549, and human high-metastatic giant cell lung carcinoma cell line PG was analyzed by Western blot.
  • HERG may serve as a molecular marker and modulating target for individualized cancer therapy.
  • [MeSH-minor] Breast Neoplasms / pathology. Cell Line, Tumor. Cell Proliferation / drug effects. Colonic Neoplasms / pathology. Drug Resistance, Neoplasm. Drug Synergism. HT29 Cells. Humans. Inhibitory Concentration 50. Transfection

  • Hazardous Substances Data Bank. Erythromycin .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16086867.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / ERG1 potassium channel; 0 / Ether-A-Go-Go Potassium Channels; 63937KV33D / Erythromycin; 80168379AG / Doxorubicin
  •  go-up   go-down


25. Franklin WA: Diagnosis of lung cancer: pathology of invasive and preinvasive neoplasia. Chest; 2000 Apr;117(4 Suppl 1):80S-89S
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of lung cancer: pathology of invasive and preinvasive neoplasia.
  • The histopathologic appearance of lung carcinoma remains an important guide to prognosis and treatment.
  • The newly revised World Health Organization classification retains the broadest pathologic categories of the older classification but includes several revisions, including the elimination of the small cell, intermediate cell type category; the addition of large cell neuroendocrine and spindle/giant cell categories; and an extended consideration of preneoplastic lesions.
  • The histopathologic classification of lung cancer is expected to continue to change as clinical practice and biological understanding of these tumors change.
  • The significance of expression of neuroendocrine markers, histologic grading of response to chemotherapy, and delineation of morphologic changes preceding the occurrence of invasive carcinoma are all areas where understanding microscopic cellular changes in the airways will be critical for clinical advance.
  • [MeSH-major] Lung / pathology. Lung Neoplasms / pathology
  • [MeSH-minor] Algorithms. Diagnosis, Differential. Humans. Mesothelioma / pathology. Neoplasm Invasiveness. Neuroendocrine Tumors / pathology. Precancerous Conditions / pathology. World Health Organization

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10777460.001).
  • [ISSN] 0012-3692
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 24
  •  go-up   go-down


26. Shimizu J, Ikeda C, Arano Y, Adachi I, Morishita M, Yamaguchi S, Ishikawa N, Watanabe G, Minato H: Advanced lung cancer invading the left atrium, treated with pneumonectomy combined with left atrium resection under cardiopulmonary bypass. Ann Thorac Cardiovasc Surg; 2010 Aug;16(4):286-90
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced lung cancer invading the left atrium, treated with pneumonectomy combined with left atrium resection under cardiopulmonary bypass.
  • Based on a bronchoscopic biopsy, it was diagnosed at a nearby clinic as an advanced left lung cancer, and he was referred to our hospital.
  • Chest computed tomography (CT) scans demonstrated a giant mass of the left lower lobe, 14 × 12 cm in size, which appeared to have invaded the left atrium (LA).
  • His postoperative course was uneventful, and he received 2 courses of adjuvant chemotherapy.
  • If CPB is used, the tension of the LA is removed by blood extraction into the bypass, and bradycardia is induced by a reduction of body temperature, probably reducing the risk of clamp dislocation.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Heart Neoplasms / surgery. Lung Neoplasms / surgery

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21057449.001).
  • [ISSN] 2186-1005
  • [Journal-full-title] Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia
  • [ISO-abbreviation] Ann Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


27. Xu F, Song D, Zhen Y: Inhibition of tumor metastasis by sodium caffeate and its effect on angiogenesis. Oncology; 2004;67(1):88-92
Hazardous Substances Data Bank. CAFFEIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The in vivo inhibitory effect of SC on metastasis and angiogenesis was examined in the Lewis lung carcinoma pulmonary metastasis model and chicken chorioallantoic membrane (CAM) model, respectively.
  • A cell attachment assay was used to evaluate inhibition by SC of the adhesion activity of human high metastatic giant cell carcinoma of the lung (PG) cells.
  • A cell invasion assay was used to evaluate the effect of SC on the ability of PG cells to cross tissue barriers.
  • [MeSH-major] Angiogenesis Inhibitors / pharmacology. Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Caffeic Acids / pharmacology. Carcinoma, Lewis Lung / drug therapy. Carcinoma, Lewis Lung / pathology
  • [MeSH-minor] Animals. Antioxidants / pharmacology. Enzyme Inhibitors / pharmacology. Flow Cytometry. Matrix Metalloproteinase 2 / drug effects. Matrix Metalloproteinase 9 / drug effects. Mice. Mice, Inbred C57BL

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 S. Karger AG, Basel
  • (PMID = 15459501.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Antioxidants; 0 / Caffeic Acids; 0 / Enzyme Inhibitors; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9; U2S3A33KVM / caffeic acid
  •  go-up   go-down


28. Choi HJ, Park IA: Fine needle aspiration cytology of metastatic choriocarcinoma presenting as a breast lump. A case report. Acta Cytol; 2004 Jan-Feb;48(1):91-4
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: While choriocarcinoma is a rapidly invasive, widely metastasizing malignancy, it responds well to chemotherapy, so it is important to obtain an early diagnosis.
  • Chest computed tomography revealed multiple nodules in both lung fields.
  • The breast mass was clinically suspected to be a metastatic lung cancer.
  • FNAC of the breast showed a malignant tumor that had been misdiagnosed as a metastatic non-small cell carcinoma of the lung.
  • CONCLUSION: The cytologic features of choriocarcinoma are quite characteristic, with side-by-side, malignant, mononucleated cells and multinucleated giant cells corresponding to cytotrophoblasts and syncytiotrophoblasts, respectively.
  • [MeSH-major] Breast Neoplasms / secondary. Choriocarcinoma / secondary. Lung Neoplasms / secondary. Nose Neoplasms / secondary. Uterine Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Fine-Needle. Cell Nucleus / pathology. Chorionic Gonadotropin, beta Subunit, Human / blood. Cough / etiology. Cough / pathology. Diagnosis, Differential. Epistaxis / etiology. Epistaxis / pathology. Female. Giant Cells / pathology. Hemoptysis / etiology. Hemoptysis / pathology. Humans. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Pregnancy. Treatment Outcome

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14969189.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human
  •  go-up   go-down


29. Shen EY, Wang WG, Li Y, Zhang SH, Zhen YS: [Inhibitory effect of endoplasmic reticulum-retained anti-type IV collagenase intrabody on invasion and proliferation of cancer cell]. Ai Zheng; 2004 Sep;23(9):1005-10
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Inhibitory effect of endoplasmic reticulum-retained anti-type IV collagenase intrabody on invasion and proliferation of cancer cell].
  • BACKGROUND & OBJECTIVE: Invasion and metastasis are significant characteristics of cancer cells, Type IV collagenase (matrix metalloproteinase-2, and-9) plays an important role in cancer invasion and metastasis.
  • This study was designed to block the secretion of type IV collagenase via intracellular antibody (intrabody) methods, and inhibit cancer invasion and metastasis.
  • METHODS: We constructed expression plasmid pcDNA3.1-ER.scFv coding for an endoplasmic reticulum (ER)- retained, single chain antibody (ER.scFv) against the type IV collagenase.
  • The intrabody gene was transfected into human giant cell pulmonary carcinoma PG cells.
  • The secretion of type IVcollagenase was detected by gelatin zymography.
  • Cell behavior was examined by invasion and proliferation assay in vitro.
  • Intrabody gene transfection significantly blocked the function and activity of type IV collegenase.
  • CONCLUSIONS: ER-retained intrabody technology may restrain the activity of type IV collagenase in protein processing and secretory pathway, and inhibits cancer cell invasion and proliferation.
  • Anti-type IV collagenase intrabody may be further used in cancer gene therapy.
  • [MeSH-major] Immunoglobulin Variable Region / biosynthesis. Lung Neoplasms / pathology. Matrix Metalloproteinase 2 / immunology. Matrix Metalloproteinase 9 / immunology
  • [MeSH-minor] Cell Line, Tumor. Cell Movement / drug effects. Cell Proliferation / drug effects. Endoplasmic Reticulum / metabolism. Genetic Vectors. Humans. Transfection

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15363191.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Immunoglobulin Variable Region; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


30. Luo Y, Hao Y, Shi TP, Deng WW, Li N: Berberine inhibits cyclin D1 expression via suppressed binding of AP-1 transcription factors to CCND1 AP-1 motif. Acta Pharmacol Sin; 2008 May;29(5):628-33
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To verify the suppressive effect of berberine on the proliferation of the human pulmonary giant cell carcinoma cell line PG and to demonstrate the mechanisms behind the antitumoral effects of berberine.
  • The cell cycle was examined by flow cytometry.
  • After treatment with berberine, the proportion of PG cells at the G0/G1 phase increased, while cells at the S and G2/M phases decreased.
  • [MeSH-minor] Amino Acid Motifs / genetics. Carcinoma, Giant Cell / drug therapy. Cell Line, Tumor. Cell Proliferation / drug effects. Cell Survival / drug effects. Dose-Response Relationship, Drug. Genes, Reporter. Humans. Luciferases / metabolism. Lung Neoplasms / drug therapy. Time Factors. Transfection


31. Ito M, Okumura K, Nishio Y: [A case of human chorionic gonadotropin-producing bladder cancer]. Hinyokika Kiyo; 2001 Jan;47(1):47-9
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since histological examination showed grade 3 transitional cell carcinoma containing giant cells that were positive for beta-human chorionic gonadotropin (beta-HCG), we made a diagnosis of beta-HCG-producing bladder cancer.
  • Because of his advanced age and poor general condition, the patient underwent partial cystectomy alone without adjuvant chemotherapy.
  • One month later, a chest X-ray film revealed multiple lung metastases, and he developed paraplegia of the lower extremities suggesting spinal metastases.
  • [MeSH-major] Carcinoma, Transitional Cell / diagnosis. Chorionic Gonadotropin, beta Subunit, Human / biosynthesis. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Cystectomy. Fatal Outcome. Humans. Lung Neoplasms / secondary. Male. Spinal Cord Neoplasms / secondary

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11235222.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chorionic Gonadotropin, beta Subunit, Human
  •  go-up   go-down


32. Seo JB, Im JG, Goo JM, Chung MJ, Kim MY: Atypical pulmonary metastases: spectrum of radiologic findings. Radiographics; 2001 Mar-Apr;21(2):403-17
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A detailed knowledge of the atypical radiologic features of a pulmonary metastasis with a good understanding of the histopathologic background is essential for correct diagnosis.
  • Squamous cell carcinoma is regarded as the most common cell type of a cavitating metastasis, but metastatic nodules from adenocarcinomas and sarcomas also cavitate occasionally.
  • Even though tumor emboli in pulmonary arteries can be seen at computed tomography, diagnosis is difficult because they are located in small or medium arteries.
  • In cases of an endobronchial or a solitary pulmonary metastasis, differentiation between bronchogenic carcinoma and metastasis is difficult.
  • A sterilized metastasis after chemotherapy is radiologically indistinguishable from a residual viable tumor.
  • Benign tumors such as uterine leiomyomas and giant cell tumors of the bone rarely metastasize to the lung.
  • [MeSH-major] Lung Neoplasms / secondary. Tomography, X-Ray Computed
  • [MeSH-minor] Calcinosis / pathology. Calcinosis / radiography. Diagnosis, Differential. Humans. Lung / pathology. Lung / radiography. Pneumothorax / pathology. Pneumothorax / radiography

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11259704.001).
  • [ISSN] 0271-5333
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 57
  •  go-up   go-down


33. Hornick JL, Jaffe ES, Fletcher CD: Extranodal histiocytic sarcoma: clinicopathologic analysis of 14 cases of a rare epithelioid malignancy. Am J Surg Pathol; 2004 Sep;28(9):1133-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Seven tumors arose in soft tissue (6 lower limb; 1 upper limb), 5 in the gastrointestinal tract (1 involving both stomach and colon, 1 ileum, 2 rectum, 1 anus), 1 in the nasal cavity, and 1 in the lung.
  • Binucleated cells were common, and 6 cases contained tumor giant cells.
  • Six patients were treated with postoperative radiation and 7 with chemotherapy (CHOP or ProMACE-MOPP).
  • Two tumors recurred locally, and 5 patients developed distant spread: 3 to lymph nodes, 1 to lung, and 1 to bone.
  • At the last follow-up, 2 patients have died of disseminated disease, 4 and 5 months following initial diagnosis.
  • Histiocytic sarcoma may arise primarily in soft tissue and shows reproducible histologic features, including abundant eosinophilic cytoplasm and a prominent inflammatory infiltrate.
  • Metastatic carcinoma, metastatic melanoma, and large cell non-Hodgkin lymphomas should be excluded by immunohistochemistry.

  • Genetic Alliance. consumer health - Epithelioid Sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15316312.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Kawamura S, Nakamura T, Oya T, Ishizawa S, Sakai Y, Tanaka T, Saito S, Fukuoka J: Advanced malignant solitary fibrous tumor in pelvis responding to radiation therapy. Pathol Int; 2007 Apr;57(4):213-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced malignant solitary fibrous tumor in pelvis responding to radiation therapy.
  • Solitary fibrous tumor (SFT) is a rare spindle cell neoplasm that is benign in most cases.
  • Herein is reported a case of a 74-year-old woman with a giant malignant SFT in the pelvis.
  • Along with massive invasion to adjacent organs and multiple lung metastases detected on radiography, biopsy from the tumor through the vaginal wall showed malignant looking spindle-cell neoplasm with increased cellularity, areas of necrosis, and high mitotic activity (5/10 high-power fields).
  • Based on pathological features and clinical presentation, diagnosis of malignant SFT was made.
  • The patient received systemic and the intra-arterial chemotherapy followed by whole pelvic radiation therapy (50 Gy).
  • Afterwards, improvement was observed radiologically and pathologically in the 12 months' follow up after the radiation therapy.
  • This is the first report related to therapeutic remarks on advanced malignant SFT.
  • [MeSH-major] Carcinoma / radiotherapy. Neoplasms, Fibrous Tissue / radiotherapy. Pelvic Neoplasms / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17316417.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down






Advertisement